License and Collaboration Agreements (Details)	1 Months Ended		3 Months Ended			9 Months Ended		12 Months Ended
	Dec. 31, 2014 USD ($)	Jan. 31, 2014 trial	Dec. 31, 2016 USD ($)	Sep. 30, 2016 USD ($) product	Sep. 30, 2015 USD ($)	Sep. 30, 2016 USD ($) product	Sep. 30, 2015 USD ($)	Dec. 31, 2015 USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License, collaboration and other revenue				$ 11,716,000	$ 1,527,000	$ 16,479,000	$ 3,038,000
Otsuka Pharmaceutical Co. Ltd | License agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Amount received upon execution of the agreement								$ 77,500,000
Additional milestone payments (up to)	$ 80,000,000
Number of additional milestone payments	3
Additional contingent milestone payment one	$ 10,000,000
Additional contingent milestone payment two	50,000,000
Additional contingent milestone payment three	$ 20,000,000
Term of license fee	10 years
Otsuka Pharmaceutical Co. Ltd | License agreement | Japan
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Refundable withholding tax								$ 15,800,000
Medinol Ltd. | License agreement
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
Additional milestone payments (up to)				$ 34,800,000.0		$ 34,800,000.0
Term of license fee						15 years
Number of registration trials initiated | trial		2
Number of products required to be successful, developed and commercialized under agreement | product				2		2
License, collaboration and other revenue				$ 2,000,000
Medinol Ltd. | License agreement | Scenario, Forecast
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]
License, collaboration and other revenue			$ 2,500,000